ARS Pharmaceuticals Inc (NAS:SPRY)
$ 8.88 -0.1 (-1.11%) Market Cap: 860.43 Mil Enterprise Value: 646.70 Mil PE Ratio: 0 PB Ratio: 3.87 GF Score: 19/100

Silverback Therapeutics Inc at H C Wainwright Bioconnect Conference (Virtual) Transcript

Jan 10, 2022 / 12:00PM GMT
Unidentified Analyst

Hello, and welcome, everyone. Thank you for joining the H.C. Wainwright BioConnect 2022 Conference. My name is Steve Verse. I'm an equity research associate here at H.C. Wainwright. Now I'd like to introduce our next presenters, Laura Shawver, CEO of Silverback Therapeutics; and Valerie Odegard, President and Chief Scientific Officer.

Silverback is focused on its proprietary ImmunoTAC platform to develop a new generation of systemically-delivered tissue-targeted therapeutics for the treatment of cancer, chronic viral infections and other serious diseases. So now I'll turn it over to Laura.

Laura K. Shawver
Silverback Therapeutics, Inc. - CEO & Director

Thank you, Stephen. Good morning, everyone. Thank you to H.C. Wainwright for the opportunity to present the Silverback company overview. And thank you to the listeners for your interest. Before I start, on Slide 2 is our disclosure about forward-looking statements in this presentation, including statements regarding our business in the expected timing and impact of future events.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot